Vanda in-licenses Lilly's NK1 receptor antagonist

Eli Lilly and Co. (NYSE:LLY) granted Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) exclusive, worldwide rights to develop and commercialize VLY-686, a small molecule neurokinin 1 (NK1) substance P receptor...